These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 29737871)

  • 1. Circulating biomarkers of hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy assessed by cardiac magnetic resonance.
    Gawor M; Śpiewak M; Kubik A; Wróbel A; Lutyńska A; Marczak M; Grzybowski J
    Biomarkers; 2018 Nov; 23(7):676-682. PubMed ID: 29737871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The usefulness of sST2 and galectin-3 as novel biomarkers for better risk stratification in hypertrophic cardiomyopathy.
    Gawor M; Śpiewak M; Janas J; Kożuch K; Wróbel A; Mazurkiewicz Ł; Baranowski R; Marczak M; Grzybowski J
    Kardiol Pol; 2017; 75(10):997-1004. PubMed ID: 28612913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usefulness of high-sensitivity cardiac troponin T and brain natriuretic peptide as biomarkers of myocardial fibrosis in patients with hypertrophic cardiomyopathy.
    Kawasaki T; Sakai C; Harimoto K; Yamano M; Miki S; Kamitani T
    Am J Cardiol; 2013 Sep; 112(6):867-72. PubMed ID: 23746480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Degree and distribution of left ventricular hypertrophy as a determining factor for elevated natriuretic peptide levels in patients with hypertrophic cardiomyopathy: insights from cardiac magnetic resonance imaging.
    Park JR; Choi JO; Han HJ; Chang SA; Park SJ; Lee SC; Choe YH; Park SW; Oh JK
    Int J Cardiovasc Imaging; 2012 Apr; 28(4):763-72. PubMed ID: 21516440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive Values of N-Terminal Pro-B-Type Natriuretic Peptide and Cardiac Troponin I for Myocardial Fibrosis in Hypertrophic Obstructive Cardiomyopathy.
    Zhang C; Liu R; Yuan J; Cui J; Hu F; Yang W; Zhang Y; Chen Y; Qiao S
    PLoS One; 2016; 11(1):e0146572. PubMed ID: 26765106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amount of left ventricular hypertrophy determines the plasma N-terminal pro-brain natriuretic peptide level in patients with hypertrophic cardiomyopathy and normal left ventricular ejection fraction.
    Kim SW; Park SW; Lim SH; Kwon SU; Choi YJ; Park MK; Lee SC; Lee SH; Park JE; Jeon ES
    Clin Cardiol; 2006 Apr; 29(4):155-60. PubMed ID: 16649724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation of global and regional myocardial mechanics with 3-dimensional speckle tracking echocardiography and relations to hypertrophy and fibrosis in hypertrophic cardiomyopathy.
    Urbano-Moral JA; Rowin EJ; Maron MS; Crean A; Pandian NG
    Circ Cardiovasc Imaging; 2014 Jan; 7(1):11-9. PubMed ID: 24275954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive values of multiple non-invasive markers for myocardial fibrosis in hypertrophic cardiomyopathy patients with preserved ejection fraction.
    Li Y; Liu J; Cao Y; Han X; Shao G; Zhou X; Gu J; Liu T; Cui Y; Shi H
    Sci Rep; 2021 Feb; 11(1):4297. PubMed ID: 33619345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Profiles of cardiovascular biomarkers according to severity stages of Chagas cardiomyopathy.
    Echeverría LE; Rojas LZ; Calvo LS; Roa ZM; Rueda-Ochoa OL; Morillo CA; Muka T; Franco OH
    Int J Cardiol; 2017 Jan; 227():577-582. PubMed ID: 27839809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Coronary Atherosclerosis and Myocardial Ischemia on Plasma Levels of High-Sensitivity Troponin T and NT-proBNP in Patients With Stable Angina.
    Caselli C; Prontera C; Liga R; De Graaf MA; Gaemperli O; Lorenzoni V; Ragusa R; Marinelli M; Del Ry S; Rovai D; Giannessi D; Aguade-Bruix S; Clemente A; Bax JJ; Lombardi M; Sicari R; Zamorano J; Scholte AJ; Kaufmann PA; Knuuti J; Underwood SR; Clerico A; Neglia D
    Arterioscler Thromb Vasc Biol; 2016 Apr; 36(4):757-64. PubMed ID: 26868212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma N-terminal pro-brain natriuretic peptide: a marker of left ventricular hypertrophy in hypertrophic cardiomyopathy.
    Brito D; Matias JS; Sargento L; Cabral MJ; Madeira HC
    Rev Port Cardiol; 2004 Dec; 23(12):1557-82. PubMed ID: 15732658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3.0 T magnetic resonance myocardial perfusion imaging for semi-quantitative evaluation of coronary microvascular dysfunction in hypertrophic cardiomyopathy.
    Yin L; Xu HY; Zheng SS; Zhu Y; Xiao JX; Zhou W; Yu SS; Gong LG
    Int J Cardiovasc Imaging; 2017 Dec; 33(12):1949-1959. PubMed ID: 28612277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma amino-terminal pro-B-type natriuretic peptide quantification in hypertrophic cardiomyopathy.
    Arteaga E; Araujo AQ; Buck P; Ianni BM; Rabello R; Mady C
    Am Heart J; 2005 Dec; 150(6):1228-32. PubMed ID: 16338263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High T2-weighted signal intensity is associated with elevated troponin T in hypertrophic cardiomyopathy.
    Gommans DF; Cramer GE; Bakker J; Michels M; Dieker HJ; Timmermans J; Fouraux MA; Marcelis CL; Verheugt FW; Brouwer MA; Kofflard MJ
    Heart; 2017 Feb; 103(4):293-299. PubMed ID: 27506680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relation of highly sensitive cardiac troponin T in hypertrophic cardiomyopathy to left ventricular mass and cardiovascular risk.
    Cramer G; Bakker J; Gommans F; Brouwer M; Kurvers M; Fouraux M; Verheugt F; Kofflard M
    Am J Cardiol; 2014 Apr; 113(7):1240-5. PubMed ID: 24513467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood-Based Cardiac Biomarkers and the Risk of Cognitive Decline, Cerebrovascular Disease, and Clinical Events.
    Gyanwali B; Lai MKP; Lui B; Liew OW; Venketasubramanian N; Richards AM; Chen C; Hilal S
    Stroke; 2021 Jul; 52(7):2275-2283. PubMed ID: 33971742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Analysis on related factors of myocardial fibrosis in patients with hypertrophic cardiomyopathy].
    Zhang Y; Wu KH; Li Q; Zhang HJ; Shang YY; Pang MJ
    Zhonghua Xin Xue Guan Bing Za Zhi; 2021 Jan; 49(1):31-36. PubMed ID: 33429483
    [No Abstract]   [Full Text] [Related]  

  • 18. N-terminal pro-brain natriuretic peptide and sudden cardiac death in hypertrophic cardiomyopathy.
    Wu G; Liu J; Wang S; Yu S; Zhang C; Wang D; Zhang M; Yang Y; Kang L; Zhao S; Hui R; Zou Y; Wang J; Song L
    Heart; 2021 Oct; 107(19):1576-1583. PubMed ID: 33361398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Electrocardiography based prediction of hypertrophy pattern and fibrosis amount in hypertrophic cardiomyopathy: comparative study with cardiac magnetic resonance imaging.
    Park CH; Chung H; Kim Y; Kim JY; Min PK; Lee KA; Yoon YW; Kim TH; Lee BK; Hong BK; Rim SJ; Kwon HM; Choi EY
    Int J Cardiovasc Imaging; 2018 Oct; 34(10):1619-1628. PubMed ID: 29728953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of Cardiac Biomarkers for Monitoring Improvement of Left Ventricular Function by Immunoadsorption Treatment in Dilated Cardiomyopathy.
    Weinmann K; Werner J; Koenig W; Rottbauer W; Walcher D; Keßler M
    Biomolecules; 2019 Oct; 9(11):. PubMed ID: 31731547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.